These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 9154824)

  • 1. Rapamycin destabilizes interleukin-3 mRNA in autocrine tumor cells by a mechanism requiring an intact 3' untranslated region.
    Banholzer R; Nair AP; Hirsch HH; Ming XF; Moroni C
    Mol Cell Biol; 1997 Jun; 17(6):3254-60. PubMed ID: 9154824
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FK506 binding protein 12 mediates sensitivity to both FK506 and rapamycin in murine mast cells.
    Fruman DA; Wood MA; Gjertson CK; Katz HR; Burakoff SJ; Bierer BE
    Eur J Immunol; 1995 Feb; 25(2):563-71. PubMed ID: 7533090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanism of action of the immunosuppressant rapamycin.
    Dumont FJ; Su Q
    Life Sci; 1996; 58(5):373-95. PubMed ID: 8594303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclosporin A, FK506, and rapamycin: binding to immunophilins and biological action.
    Bierer BE
    Chem Immunol; 1994; 59():128-55. PubMed ID: 7524531
    [No Abstract]   [Full Text] [Related]  

  • 5. Molecular mechanisms of immunosuppression by cyclosporine, FK506, and rapamycin.
    Cardenas ME; Zhu D; Heitman J
    Curr Opin Nephrol Hypertens; 1995 Nov; 4(6):472-7. PubMed ID: 8591053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of 70-kDa S6 kinase, induced by the cytokines interleukin-3 and erythropoietin and inhibited by rapamycin, is not an absolute requirement for cell proliferation.
    Calvo V; Wood M; Gjertson C; Vik T; Bierer BE
    Eur J Immunol; 1994 Nov; 24(11):2664-71. PubMed ID: 7957559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapamycin resistance in ataxia-telangiectasia.
    Beamish H; Williams R; Chen P; Khanna KK; Hobson K; Watters D; Shiloh Y; Lavin M
    Oncogene; 1996 Sep; 13(5):963-70. PubMed ID: 8806686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanism of action of rapamycin: new insights into the regulation of G1-phase progression in eukaryotic cells.
    Wiederrecht GJ; Sabers CJ; Brunn GJ; Martin MM; Dumont FJ; Abraham RT
    Prog Cell Cycle Res; 1995; 1():53-71. PubMed ID: 9552353
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanism of action of rapamycin (Sirolimus, Rapamune).
    Molnar-Kimber KL
    Transplant Proc; 1996 Apr; 28(2):964-9. PubMed ID: 8623482
    [No Abstract]   [Full Text] [Related]  

  • 10. Dominant mutations confer resistance to the immunosuppressant, rapamycin, in variants of a T cell lymphoma.
    Dumont FJ; Staruch MJ; Grammer T; Blenis J; Kastner CA; Rupprecht KM
    Cell Immunol; 1995 Jun; 163(1):70-9. PubMed ID: 7538911
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Roles of peptidyl-prolyl cis-trans isomerase and calcineurin in the mechanisms of antimalarial action of cyclosporin A, FK506, and rapamycin.
    Bell A; Wernli B; Franklin RM
    Biochem Pharmacol; 1994 Aug; 48(3):495-503. PubMed ID: 7520696
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells.
    Sabers CJ; Martin MM; Brunn GJ; Williams JM; Dumont FJ; Wiederrecht G; Abraham RT
    J Biol Chem; 1995 Jan; 270(2):815-22. PubMed ID: 7822316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FAP48, a new protein that forms specific complexes with both immunophilins FKBP59 and FKBP12. Prevention by the immunosuppressant drugs FK506 and rapamycin.
    Chambraud B; Radanyi C; Camonis JH; Shazand K; Rajkowski K; Baulieu EE
    J Biol Chem; 1996 Dec; 271(51):32923-9. PubMed ID: 8955134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure-activity studies of rapamycin analogs: evidence that the C-7 methoxy group is part of the effector domain and positioned at the FKBP12-FRAP interface.
    Luengo JI; Yamashita DS; Dunnington D; Beck AK; Rozamus LW; Yen HK; Bossard MJ; Levy MA; Hand A; Newman-Tarr T
    Chem Biol; 1995 Jul; 2(7):471-81. PubMed ID: 9383449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The chemistry of signal transduction.
    Clardy J
    Proc Natl Acad Sci U S A; 1995 Jan; 92(1):56-61. PubMed ID: 7529414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapamycin inhibition of the G1 to S transition is mediated by effects on cyclin D1 mRNA and protein stability.
    Hashemolhosseini S; Nagamine Y; Morley SJ; Desrivières S; Mercep L; Ferrari S
    J Biol Chem; 1998 Jun; 273(23):14424-9. PubMed ID: 9603954
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapamycin-FKBP12 blocks proliferation, induces differentiation, and inhibits cdc2 kinase activity in a myogenic cell line.
    Jayaraman T; Marks AR
    J Biol Chem; 1993 Dec; 268(34):25385-8. PubMed ID: 7503980
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lessons from molecular matchmakers.
    Teague S
    Nat Struct Biol; 1995 May; 2(5):360-1. PubMed ID: 7545076
    [No Abstract]   [Full Text] [Related]  

  • 19. Design and synthesis of a rapamycin-based high affinity binding FKBP12 ligand.
    Chakraborty TK; Weber HP; Nicolaou KC
    Chem Biol; 1995 Mar; 2(3):157-61. PubMed ID: 9383417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclosporin A, FK506 and rapamycin: more than just immunosuppression.
    Kunz J; Hall MN
    Trends Biochem Sci; 1993 Sep; 18(9):334-8. PubMed ID: 7694398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.